These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1846868)

  • 1. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin.
    Mortola JF; Girton L; Fischer U
    J Clin Endocrinol Metab; 1991 Feb; 72(2):252A-252F. PubMed ID: 1846868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome.
    Mezrow G; Shoupe D; Spicer D; Lobo R; Leung B; Pike M
    Fertil Steril; 1994 Nov; 62(5):932-7. PubMed ID: 7926137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications of gonadotropin-releasing hormone analogues in the treatment of premenstrual syndrome.
    Mortola JF
    Clin Obstet Gynecol; 1993 Sep; 36(3):753-63. PubMed ID: 8403622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
    Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
    JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Premenstrual syndrome.
    DeVane GW
    J Clin Endocrinol Metab; 1991 Feb; 72(2):250-1. PubMed ID: 1846867
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of estrogen with and without progestin on urinary incontinence.
    Hendrix SL; Cochrane BB; Nygaard IE; Handa VL; Barnabei VM; Iglesia C; Aragaki A; Naughton MJ; Wallace RB; McNeeley SG
    JAMA; 2005 Feb; 293(8):935-48. PubMed ID: 15728164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results.
    Pickar JH; Yeh IT; Wheeler JE; Cunnane MF; Speroff L
    Fertil Steril; 2003 Nov; 80(5):1234-40. PubMed ID: 14607581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
    Pickar JH; Yeh I; Wheeler JE; Cunnane MF; Speroff L
    Fertil Steril; 2001 Jul; 76(1):25-31. PubMed ID: 11438315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate.
    Cedars MI; Lu JK; Meldrum DR; Judd HL
    Obstet Gynecol; 1990 Apr; 75(4):641-5. PubMed ID: 2138265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study.
    Harden CL; Herzog AG; Nikolov BG; Koppel BS; Christos PJ; Fowler K; Labar DR; Hauser WA
    Epilepsia; 2006 Sep; 47(9):1447-51. PubMed ID: 16981859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1995 Jan; 273(3):199-208. PubMed ID: 7807658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-ischemic effect of chronic oestrogen replacement therapy alone or in combination with medroxyprogesterone acetate in different replacement schemes.
    Cerquetani E; Leonardo F; Pagnotta P; Galetta P; Onorati D; Fini M; Rosano GM
    Maturitas; 2001 Sep; 39(3):245-51. PubMed ID: 11574184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome.
    Berga SL; Yen SS
    Clin Endocrinol (Oxf); 1989 Feb; 30(2):177-84. PubMed ID: 2532984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
    Utian WH; Shoupe D; Bachmann G; Pinkerton JV; Pickar JH
    Fertil Steril; 2001 Jun; 75(6):1065-79. PubMed ID: 11384629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.
    Heiss G; Wallace R; Anderson GL; Aragaki A; Beresford SA; Brzyski R; Chlebowski RT; Gass M; LaCroix A; Manson JE; Prentice RL; Rossouw J; Stefanick ML;
    JAMA; 2008 Mar; 299(9):1036-45. PubMed ID: 18319414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women.
    Barrett-Connor E; Slone S; Greendale G; Kritz-Silverstein D; Espeland M; Johnson SR; Waclawiw M; Fineberg SE
    Maturitas; 1997 Jul; 27(3):261-74. PubMed ID: 9288699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism.
    Lobo RA; Bush T; Carr BR; Pickar JH
    Fertil Steril; 2001 Jul; 76(1):13-24. PubMed ID: 11438314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators.
    Greendale GA; Reboussin BA; Sie A; Singh HR; Olson LK; Gatewood O; Bassett LW; Wasilauskas C; Bush T; Barrett-Connor E
    Ann Intern Med; 1999 Feb; 130(4 Pt 1):262-9. PubMed ID: 10068383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled, cross-over trial to assess the side effects of medroxyprogesterone acetate in hormone replacement therapy.
    Kirkham C; Hahn PM; Van Vugt DA; Carmichael JA; Reid RL
    Obstet Gynecol; 1991 Jul; 78(1):93-7. PubMed ID: 1828550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen.
    Sundström I; Nyberg S; Bixo M; Hammarbäck S; Bäckström T
    Acta Obstet Gynecol Scand; 1999 Nov; 78(10):891-9. PubMed ID: 10577620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.